{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T15:51:29Z","timestamp":1791388289858,"version":"4.3.3"},"reference-count":10,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The French Journal of Urology"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.fjurol.2026.103162","type":"journal-article","created":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T16:01:38Z","timestamp":1783440098000},"page":"103162","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Evidence thresholds for novel therapeutic strategies in prostate cancer: A consensus statement from the Prostate Cancer Committee of the French Urological Association"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6935-3873","authenticated-orcid":false,"given":"Michael","family":"Baboudjian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Barret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Brureau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"Fiard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"Fromont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Dariane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1158-0082","authenticated-orcid":false,"given":"Arthur","family":"Peyrottes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilhem","family":"Roubaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00eble","family":"Renard-Penna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sargos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Supiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9a","family":"Turpin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6004-2152","authenticated-orcid":false,"given":"Guillaume","family":"Ploussard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.fjurol.2026.103162_bib0055","doi-asserted-by":"crossref","first-page":"102717","DOI":"10.1016\/j.fjurol.2024.102717","article-title":"French AFU Cancer Committee Guidelines\u00a0\u2013\u00a0Update 2024-2026: prostate cancer\u00a0\u2013\u00a0diagnosis and management of localised disease","volume":"34","author":"Ploussard","year":"2024","journal-title":"Fr J Urol"},{"issue":"12","key":"10.1016\/j.fjurol.2026.103162_bib0060","doi-asserted-by":"crossref","first-page":"102710","DOI":"10.1016\/j.fjurol.2024.102710","article-title":"French AFU Cancer Committee Guidelines\u00a0\u2013\u00a0Update 2024\u20132026: prostate cancer\u00a0\u2013\u00a0management of metastatic disease and castration resistance","volume":"34","author":"Ploussard","year":"2024","journal-title":"Fr J Urol"},{"key":"10.1016\/j.fjurol.2026.103162_bib0065","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1200\/JCO-25-02834","article-title":"Trial design and objectives for patients with prostate cancer: recommendations from the prostate cancer working group 4","volume":"44","author":"Armstrong","year":"2026","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.fjurol.2026.103162_bib0070","doi-asserted-by":"crossref","first-page":"3097","DOI":"10.1200\/JCO.2017.73.9987","article-title":"Metastasis-free survival is a strong surrogate of overall survival in localized prostate cancer","volume":"35","author":"Xie","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.fjurol.2026.103162_bib0075","first-page":"1","article-title":"The state of intermediate clinical endpoints as surrogates for overall survival in prostate cancer in 2024","volume":"64","author":"Miszczyk","year":"2024","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.fjurol.2026.103162_bib0080","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMoa2603878","article-title":"Perioperative apalutamide in high-risk localized prostate cancer","author":"Taplin","year":"2026","journal-title":"N Engl J Med"},{"issue":"18","key":"10.1016\/j.fjurol.2026.103162_bib0085","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1200\/JCO.23.00762","article-title":"Prognostic impact of prostate-specific antigen at 6 months after radiotherapy in localized prostate cancer: an individual patient data analysis of randomized trials","volume":"42","author":"Kwak","year":"2024","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.fjurol.2026.103162_bib0090","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1038\/s41585-021-00470-4","article-title":"Treatment and trials in non-metastatic castration-resistant prostate cancer","volume":"18","author":"Lokeshwar","year":"2021","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.fjurol.2026.103162_bib0095","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1200\/JCO.23.01535","article-title":"Radiographic progression-free survival and clinical progression-free survival as potential surrogates for overall survival in men with metastatic hormone-sensitive prostate cancer","volume":"42","author":"Halabi","year":"2024","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.fjurol.2026.103162_bib0100","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/EVIDoa2200195","article-title":"Meta-analysis of candidate surrogate end points in advanced prostate cancer","volume":"2","author":"Gharzai","year":"2023","journal-title":"NEJM Evid"}],"container-title":["The French Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393026000938?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393026000938?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,7]],"date-time":"2026-10-07T14:58:34Z","timestamp":1791385114000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950393026000938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":10,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2950393026000938"],"URL":"https:\/\/doi.org\/10.1016\/j.fjurol.2026.103162","relation":{},"ISSN":["2950-3930"],"issn-type":[{"value":"2950-3930","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Evidence thresholds for novel therapeutic strategies in prostate cancer: A consensus statement from the Prostate Cancer Committee of the French Urological Association","name":"articletitle","label":"Article Title"},{"value":"The French Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fjurol.2026.103162","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"103162"}}